Amneal Pharmaceuticals Free Cash Flow (FCF) History (AMRX)
Amneal Pharmaceuticals reported $269.9M in free cash flow for fiscal 2025, an increase of 11.00% from the previous fiscal year, with a free cash flow margin of 8.94%.
View full Amneal Pharmaceuticals company overviewAmneal Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $269.9M | $26.8M | +11.00% | +8.94% |
| 2024 | 2024-12-31 | $243.2M | −$59.2M | −19.57% | +8.70% |
| 2023 | 2023-12-31 | $302.4M | $283.7M | +1517.51% | +12.63% |
| 2022 | 2022-12-31 | $18.7M | −$175.4M | −90.37% | +0.84% |
| 2021 | 2021-12-31 | $194.1M | −$128.5M | −39.83% | +9.27% |
| 2020 | 2020-12-31 | $322.6M | $368.0M | — | +16.19% |
| 2019 | 2019-12-31 | −$45.5M | −$212.6M | — | −2.80% |
| 2018 | 2018-12-31 | $167.1M | $27.7M | +19.89% | +10.05% |
| 2017 | 2017-12-31 | $139.4M | $147.1M | — | +13.49% |
| 2016 | 2016-12-31 | −$7.7M | — | — | −0.76% |
Amneal Pharmaceuticals quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$51.9M | −$112.9M | — | −6.52% |
| Q1 2026 | 2026-03-31 | −$34.9M | −$29.2M | — | −4.83% |
| Q4 2025 | 2025-12-31 | $108.5M | $5.6M | +5.46% | +13.33% |
| Q3 2025 | 2025-09-30 | $106.2M | −$18.7M | −14.96% | +13.53% |
| Q2 2025 | 2025-06-30 | $61.0M | $32.0M | +110.08% | +8.42% |
| Q1 2025 | 2025-03-31 | −$5.8M | $7.9M | — | −0.83% |
| Q4 2024 | 2024-12-31 | $102.9M | −$23.0M | −18.29% | +14.09% |
| Q3 2024 | 2024-09-30 | $124.8M | $55.1M | +79.03% | +17.77% |
| Q2 2024 | 2024-06-30 | $29.0M | $52.4M | — | +4.14% |
| Q1 2024 | 2024-03-31 | −$13.6M | −$143.6M | — | −2.06% |
| Q4 2023 | 2023-12-31 | $126.0M | $160.7M | — | +20.42% |
| Q3 2023 | 2023-09-30 | $69.7M | −$4.7M | −6.37% | +11.25% |
| Q2 2023 | 2023-06-30 | −$23.3M | $107.2M | — | −3.90% |
| Q1 2023 | 2023-03-31 | $130.0M | $20.5M | +18.69% | +23.32% |
| Q4 2022 | 2022-12-31 | −$34.8M | −$80.5M | — | −5.70% |
| Q3 2022 | 2022-09-30 | $74.5M | $2.8M | +3.84% | +13.65% |
| Q2 2022 | 2022-06-30 | −$130.6M | −$70.8M | — | −23.34% |
| Q1 2022 | 2022-03-31 | $109.5M | −$26.8M | −19.66% | +22.01% |
| Q4 2021 | 2021-12-31 | $45.8M | −$30.7M | −40.12% | +8.52% |
| Q3 2021 | 2021-09-30 | $71.7M | $37.9M | +112.29% | +13.57% |
| Q2 2021 | 2021-06-30 | −$59.7M | −$230.4M | — | −11.17% |
| Q1 2021 | 2021-03-31 | $136.4M | $94.7M | +227.31% | +27.65% |
| Q4 2020 | 2020-12-31 | $76.4M | $131.8M | — | +14.98% |
| Q3 2020 | 2020-09-30 | $33.8M | −$93.1M | −73.37% | +6.51% |
| Q2 2020 | 2020-06-30 | $170.7M | $161.2M | +1705.66% | +36.73% |
| Q1 2020 | 2020-03-31 | $41.7M | $168.1M | — | +8.36% |
| Q4 2019 | 2019-12-31 | −$55.4M | −$295.0M | — | −13.94% |
| Q3 2019 | 2019-09-30 | $126.9M | $91.2M | +255.75% | +33.54% |
| Q2 2019 | 2019-06-30 | $9.5M | $125.1M | — | +2.34% |
| Q1 2019 | 2019-03-31 | −$126.4M | −$133.9M | — | −28.33% |
| Q4 2018 | 2018-12-31 | $239.6M | $181.7M | +313.35% | — |
| Q3 2018 | 2018-09-30 | $35.7M | — | — | +7.48% |
| Q2 2018 | 2018-06-30 | −$115.7M | — | — | −27.96% |
| Q1 2018 | 2018-03-31 | $7.5M | — | — | +2.74% |
| Q3 2017 | 2017-09-30 | $58.0M | — | — | +22.76% |
Amneal Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $322.6M to $269.9M, a compound annual decline of 3.50%. Amneal Pharmaceuticals's latest reported quarter, Q2 2026, generated −$51.9M in free cash flow, a decrease of $112.9M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Amneal Pharmaceuticals filings at SEC.gov ↗